Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
Bristol Myers Squibb’ Karuna Therapeutics Buyout; Orchard Therapeutics’ Lenmeldy FDA Approval; Madrigal Pharmaceuticals’ Rezdiffra FDA Approval; AstraZeneca’s Acquisition of Amolyt Pharma; Prilenia’s Pridopidine EU Marketing Approval
Bristol Myers Squibb Enhances Neuroscience Arm with Karuna Therapeutics Buyout Bristol Myers Squibb has declared the finalization of its purchase of Karuna Therapeutics, Inc. With this acquisition concluded Karuna’s shares are no longer being traded on the Nasdaq Global Select Market, as Karuna is now fully owned by Bristol Myers Squibb. “We are thrilled to broaden our range of neuroscience offerings with the addition of Karuna to Bristol Myers Squibb,” stated Chris Boerner, Ph.D., Chief Executive Officer of Bristol Myers Squibb. “Crucially, this agreement supports our dedication to enhancing BMS’s…
Promising Nephrotic Syndrome Treatments: A Look into the Future
Nephrotic syndrome is a clinical condition characterized by significant protein in the urine (exceeding 40 mg/m2/h), leading to low levels of albumin (below 30 g/L), which in turn causes high levels of lipids, swelling, and a range of associated complications. The epidemiological assessment of nephrotic syndrome plays a pivotal role in understanding the prevalence, distribution, and impact of this renal disorder. To comprehensively evaluate the landscape of nephrotic syndrome, assumptions, and rationales are employed to delineate the primary and secondary glomeruli nephropathies contributing to the overall burden of the syndrome.…
Unveiling the Potential of TROP-2 Inhibitors: A New Frontier in Cancer Treatment
Trophoblast cell surface antigen-2 (TROP-2) is a 35-kDa protein found on cell membranes, made of sugars and a protein chain, serving as a transmitter of calcium signals. It is produced by the TACSTD2 gene and shares a structural similarity with the epithelial cell adhesion molecule (EpCAM). TROP2, although identified for its promising potential in cancer treatment some years ago, is now emerging as a significant protein target. With the rise of targeted therapies and immunotherapies, TROP2 has gained attention due to its crucial role in cancer cell proliferation and spread.…